News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
597,721 Results
Type
Article (24756)
Company Profile (216)
Press Release (572745)
Multimedia
Podcasts (117)
Webinars (9)
Section
Business (193075)
Career Advice (405)
Deals (29596)
Drug Delivery (87)
Drug Development (74663)
Employer Resources (38)
FDA (14014)
Job Trends (10970)
News (289349)
Policy (23415)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (6)
Academia (1374)
Academic (1)
Accelerated approval (60)
ADA (41)
Adcomms (29)
Allergies (148)
Alliances (40959)
ALS (213)
Alzheimer's disease (1669)
Antibody-drug conjugate (ADC) (544)
Approvals (14566)
Artificial intelligence (578)
ASCO (302)
Autoimmune disease (369)
Automation (46)
Bankruptcy (297)
Best Places to Work (9010)
BIO (66)
Biologics (1)
BIOSECURE Act (13)
Biosimilars (194)
BioSpace Insights (73)
Biotechnology (147)
Bladder cancer (211)
Brain cancer (79)
Breast cancer (816)
Cancer (6309)
Cardiovascular disease (489)
Career advice (348)
Career pathing (7)
CAR-T (407)
CDC (12)
Celiac Disease (2)
Cell therapy (1116)
Cervical cancer (46)
Clinical research (66982)
Collaboration (2115)
Commercialization (5)
Company closure (5)
Compensation (1530)
Complete response letters (86)
COVID-19 (1497)
CRISPR (125)
C-suite (1145)
Cystic fibrosis (161)
Data (8474)
Decentralized trials (1)
Denatured (18)
Depression (183)
Dermatology (95)
Diabetes (606)
Diagnostics (5097)
Digital health (51)
Diversity (3)
Diversity, equity & inclusion (10)
Drug discovery (317)
Drug pricing (100)
Drug shortages (23)
Duchenne muscular dystrophy (331)
Earnings (80746)
Editorial (35)
Employer branding (5)
Employer resources (37)
Events (104089)
Executive appointments (989)
FDA (17885)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (25)
Frontotemporal dementia (31)
Funding (1641)
Gene editing (268)
Generative AI (44)
Gene therapy (885)
GLP-1 (845)
Government (2144)
Grass and pollen (3)
Guidances (367)
Healthcare (13264)
Hematology (174)
HIV (88)
Huntington's disease (67)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (115)
Immunology and inflammation (293)
Immuno-oncology (108)
Indications (223)
Infectious disease (1769)
Inflammatory bowel disease (221)
Inflation Reduction Act (7)
Influenza (101)
Intellectual property (304)
Interviews (56)
IPO (14213)
IRA (20)
Job creations (2383)
Job search strategy (319)
JPM (47)
Kidney cancer (20)
Labor market (26)
Layoffs (313)
Leadership (7)
Legal (5725)
Licensing (10)
Liver cancer (88)
Longevity (31)
Lung cancer (862)
Lymphoma (492)
Machine learning (44)
Management (9)
Manufacturing (980)
Marketing (12)
MASH (210)
Medical device (10625)
Medtech (10804)
Mergers & acquisitions (16604)
Metabolic disorders (1490)
mRNA (179)
Multiple sclerosis (185)
NASH (15)
Neurodegenerative disease (475)
Neuropsychiatric disorders (108)
Neuroscience (3260)
Neurotech (1)
NextGen: Class of 2026 (4320)
Non-profit (1979)
Now hiring (18)
Obesity (651)
Opinion (169)
Ovarian cancer (238)
Pain (265)
Pancreatic cancer (331)
Parkinson's disease (376)
Partnered (26)
Patents (603)
Patient recruitment (817)
Peanut (50)
People (48631)
Pharmaceutical (40)
Pharmacy benefit managers (15)
Phase 1 (21111)
Phase 2 (29712)
Phase 3 (21651)
Pipeline (10205)
Policy (174)
Postmarket research (2316)
Preclinical (8765)
Press Release (63)
Prostate cancer (340)
Psychedelics (77)
Radiopharmaceuticals (343)
Rare diseases (1256)
Real estate (3920)
Recruiting (17)
Regulatory (20915)
Reports (30)
Research institute (1610)
Resumes & cover letters (56)
Rett syndrome (50)
RNA editing (25)
RSV (60)
Schizophrenia (168)
Series A (297)
Series B (214)
Service/supplier (5)
Sickle cell disease (125)
Special edition (18)
Spinal muscular atrophy (174)
Sponsored (32)
Startups (2846)
Stomach cancer (16)
Supply chain (95)
Tariffs (38)
The Weekly (97)
Vaccines (605)
Venture capital (88)
Weight loss (382)
Women's health (106)
Worklife (3)
Date
Today (80)
Last 7 days (509)
Last 30 days (2220)
Last 365 days (27225)
2026 (17412)
2025 (27002)
2024 (30930)
2023 (34499)
2022 (43898)
2021 (46656)
2020 (42304)
2019 (31577)
2018 (23778)
2017 (24872)
2016 (23516)
2015 (29554)
2014 (25223)
2013 (20995)
2012 (22976)
2011 (23230)
2010 (22771)
Location
Africa (352)
Alabama (90)
Alaska (4)
Arizona (347)
Arkansas (12)
Asia (28750)
Australia (4330)
California (13770)
Canada (3634)
China (1445)
Colorado (575)
Connecticut (552)
Delaware (363)
Europe (57209)
Florida (2041)
Georgia (436)
Hawaii (4)
Idaho (52)
Illinois (957)
India (103)
Indiana (500)
Iowa (20)
Japan (573)
Kansas (122)
Kentucky (44)
Louisiana (51)
Maine (31)
Maryland (1515)
Massachusetts (10001)
Michigan (332)
Minnesota (675)
Mississippi (5)
Missouri (144)
Montana (27)
Nebraska (13)
Nevada (124)
New Hampshire (72)
New Jersey (3569)
New Mexico (24)
New York (3588)
North Carolina (1701)
North Dakota (11)
Northern California (7005)
Ohio (361)
Oklahoma (18)
Oregon (32)
Pennsylvania (2700)
Puerto Rico (25)
Rhode Island (40)
South America (539)
South Carolina (81)
South Dakota (1)
Southern California (5520)
Tennessee (167)
Texas (2274)
United States (47670)
Utah (406)
Vermont (1)
Virginia (265)
Washington D.C. (53)
Washington State (1099)
West Virginia (2)
Wisconsin (123)
597,721 Results for "xcyte therapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
Assessing shared failures with AI is key to cell and gene therapy’s evolution
If we guard our secrets, patients suffer. Only through a commitment to transparency and data sharing—and artificial intelligence—can we make cell and gene therapies safer and more effective.
August 18, 2026
·
5 min read
·
Alexander Seyf
Manufacturing
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
ITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.
August 11, 2026
·
1 min read
·
Gabrielle Masson
Press Releases
Mercury Medical Awarded Respiratory Therapy, Resuscitation Devices Agreement with Premier, Inc.
July 22, 2026
·
2 min read
Press Releases
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
• Company secures $10 million line of credit supported by OS Therapies UK tax credits
July 2, 2026
·
7 min read
Manufacturing
Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR T therapy
ElevateBio will be the primary source of Kyverna’s autologous CAR T cell therapy for anticipated U.S. and global launches in autoimmune indications.
July 29, 2026
·
2 min read
·
Nick Paul Taylor
Neuroscience
UniQure’s chronic epilepsy gene therapy ‘should be on investors’ radar’
As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”
June 22, 2026
·
3 min read
·
Tristan Manalac
Opinion
Gene therapy’s evidence problem—lessons from recent FDA decisions
Comprehending the spate of recent rejections in the cell and gene therapy space may require looking no further than early-stage clinical trials of candidates from REGENXBIO, Excision BioTherapeutics and Intellia Therapeutics.
May 4, 2026
·
6 min read
·
Jenna DiRito
FDA
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
The FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10 to 3 in favor of Replimune’s immunotherapy for advanced melanoma in combination with Bristol Myers Squibb’s Opdivo, but trial design was a major sticking point as the panel deliberated.
July 30, 2026
·
5 min read
·
Michael Gibney
Press Releases
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
August 12, 2026
·
10 min read
Manufacturing
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.
July 22, 2026
·
2 min read
·
Nick Paul Taylor
1 of 59,773
Next
